This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Depomed FDA Panel Live Blog Recap

BETHESDA, Md. ( TheStreet) -- An advisory panel convened by the U.S. Food and Drug Administration meets today to review an new therapy for menopausal hot flashes developed by Depomed (DEPO - Get Report).

Joining me this morning to cover the Depomed FDA panel live blog are Zacks analyst Jason Napodano and biotech investor and TheStreet contributor Aafia Chaudhry. Jason and Aaafia are bullish and bearish on Depomed, respectively, so I'm hoping for some fireworks between the two along with insightful analysis of the panel's proceedings.

The Depomed drug being reviewed today is Sefelsa, a long-acting form of the generic drug gabapentin, which is currently approved to treat shingles-related nerve pain.

An FDA review posted to the agency's web site Thursday found that Sefelsa does provide some relief to menopausal women but also questioned the durability of the drug's effect. Studies conducted demonstrated Sefelsa can lower the incidence of hot flashes for four weeks but response falls off when measured at 12 or 24 weeks, FDA said.

The FDA also raised concerns about Sefelsa's link to patient reports of suicidal thoughts.

Experts on the FDA's advisory panel are being asked to review the efficacy and safety data for Sefelsa and vote on whether or not to recommend the drug for approval. The final decision on approval rests with FDA. The agency is expected to make its decision known by May 31.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DEPO $15.53 -3.80%
AAPL $92.69 -0.59%
FB $119.49 1.40%
GOOG $711.11 1.40%
TSLA $214.84 1.60%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs